OPKO Adds to Growing Tech Portfolio

opko-160x160

Zebra Biologics, Inc

opko-160x160

Opko Press Release:  

MIAMI, Oct 10, 2013 (BUSINESS WIRE) — OPKO Health, Inc. has agreed to make an investment in Zebra Biologics, Inc. (“Zebra”), a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drug targets. Zebra’s patented platform is an advanced version of a core technology that underlies the discovery and commercial success of AbbVie Inc.’s Humira(TM), developed by Richard Lerner, M.D., at The Scripps Research Institute. The technology allows for the selection of antibodies for function rather than through simple binding. Zebra has already developed an early pre-clinical pipeline of candidate antibodies with significant commercial potential in regulating diabetes and obesity, cancer, and treatment of neurological disease.

In addition to Phillip Frost, M.D., OPKO’s Chairman and Chief Executive Officer, Zebra’s directors and founders also include Dr. Lerner; Dr. Ronald M. Lindsay, a director and Executive Vice President for Strategic Planning of Sequenom, Inc.  a company providing innovative diagnostic testing and genetic analysis solutions; Mr. Gao Feng, chairman and president of Beijing based Hongye International Investment Group, which operates in the energy, natural resources, finance and bio-pharmaceuticals industries; and Dr. Paul Greengard, Vincent Astor Professor at Rockefeller University and recipient of a 2000 Nobel Prize for his work concerning signal transduction in the nervous system.

“This participation is in keeping with a core strategy of investing in other companies that have valuable proprietary technology and significant future potential for OPKO,” said Dr. Frost. “We are hopeful that our portfolio of investments will continue to appreciate in value as the companies and technologies mature. In some cases, our investments offer opportunities for OPKO to obtain new products; as well as the possibility to monetize them at an appropriate time.”

ABOUT OPKO HEALTH, INC.

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.

SAFE HARBOR STATEMENT

This press release includes forward looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Such statements may relate to OPKO’s plans, objectives and expected financial and operating results, including statements regarding the commercial potential of Zebra’s early pre-clinical pipeline of candidate antibodies, expected benefits from OPKO’s investment in Zebra and other companies with valuable proprietary technology, the value of OPKO’s portfolio of investments and whether the investments will continue to appreciate in value, whether the investments offer opportunities for new products, and whether OPKO will be able to monetize the investments at the appropriate time. The words “may,” “could,” “would,” “will,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” and similar expressions or variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond OPKO’s ability to control. The risks and uncertainties that may affect forward looking statements include those described in OPKO’s filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors For more details about the risks and uncertainties related to OPKO’s business, refer to OPKO’s filings with the Securities and Exchange Commission. OPKO undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

SOURCE: OPKO Health, Inc.

About Absolute Day Trader Picks

This is a site sponsored and driven by content supplied and aggregated  by Frank Magliochetti and Parcae Capital Corporation.  It will highlight emerging growth companies and picks made by Frank Magliochetti and his team of professionals.

If you have a company interested in having our team review for our Day Trading Pick please contact us by clicking here.

Day Trader Picks

Absolute Day Trader Picks

media-crush-logo_thumb

Featured on Media Crush

Absolute Day Trader Picks was recently a featured post on Media Crush!

Many months ago ADTP Frank Magliochetti chose OPKO Health Inc as a featured company to watch.

Lo and behold the pick has been a hot one with OPKO Health Inc heating up many of the trend setting stock analysts sites.

CLICK HERE to take a look at what our marketing company had to say recently on their blog about ADTP.

 

Media Crush LLC

OPKO to List on Tel Aviv for Prolor Deal

Tel Aviv Stock Exchange

Billionaire Phillip  Frost to List Shares…

Tel Aviv Stock ExchangeOpko Health Inc. (OPK:US), led by billionaire Phillip Frost, is set to list shares on the Tel Aviv Stock Exchange as it seeks to complete the acquisition of Israeli drugmaker Prolor Biotech Inc. (PBTH:US)

 

OPKO Health IncShares of the Miami-based drug developer, which are already listed on the New York Stock Exchange, will begin trading in Tel Aviv on Aug. 21, a bourse spokeswoman said by telephone today. In October, the stock will enter the Tel Aviv 25 Index (TA-25), a gauge of the exchange’s largest companies by market value, she said.

Prolor-Biotech_OPKOOpko’s listing would enable it to pay Prolor shareholders in locally listed stock. The deal announced in April gave them 0.9951 Opko shares for each stock in Prolor. While the share swap valued Prolor at $480 million in April, a 12 percent increase in Opko’s shares since then has boosted the value to about $540 million.

Prolor’s stock, which will be delisted, has gained 27 percent since the deal was announced. The transaction is expected to close in the second half of this year, provided Opko and Prolor shareholders approve the merger in a vote on Aug. 28.

After selling Ivax Corp. to Teva (TEVA) for $7.4 billion in 2006, Frost and his associates began assembling Opko, a health-care holding company for diagnostic equipment and medical products. Frost is the chairman and largest shareholder in both Opko and Prolor and one of Prolor’s early investors. He’s also chairman of Teva.

Sourced From:
http://www.businessweek.com/news/2013-08-19/billionaire-frost-s-opko-to-list-in-tel-aviv-for-prolor-deal
by David Wainer in Tel Aviv – Bloomberg

About Absolute Day Trader Picks

This is a site sponsored and driven by content supplied and aggregated  by Frank Magliochetti and Parcae Capital Corporation.  It will highlight emerging growth companies and picks made by Frank Magliochetti and his team of professionals.

If you have a company interested in having our team review for our Day Trading Pick please contact us by clicking here.

Day Trader Picks

OPKO Rayaldy News:

OPKO Health Inc

Surpasses 50% enrollment in second phase III trials

OPKO Health IncOPKO Health, Inc. has surpassed 50 per cent enrollment in the second phase III trial of Rayaldy to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. This trial is the second of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of Rayaldy as a new treatment for SHPT in the targeted population.

The endpoints of both studies, which are being conducted in parallel, include vitamin D status and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone (PTH).

Each of the two phase III trials will involve 210 patients recruited at approximately 40 sites in the US. These patients are being stratified by CKD stage and randomized in a 2:1 fashion to receive six months of treatment with either Rayaldy or placebo. Dosing with Rayaldy is titrated, as necessary, to achieve the desired blood concentration and the targeted reduction in PTH.

“I am pleased to report that these pivotal trials with Rayaldy Capsules are progressing as planned toward completion in the first half of 2014,” stated Phillip Frost, MD, OPKO’s chairman and chief executive officer. “Top-line data are expected in mid-2014. We believe Rayaldy will prove to be superior to high monthly doses of prescription vitamin D2, a common therapeutic approach which has been shown unreliable in correcting vitamin D insufficiency in patients with chronic kidney disease and generally ineffective in controlling elevated levels of parathyroid hormone. We look forward to advancing the standard of care for this patient population when Rayaldy is ultimately approved for marketing.”

Rayaldy is a first-in-class oral vitamin D prohormone treatment being developed for SHPT in stage 3 and 4 CKD patients with vitamin D insufficiency. It has a proprietary modified-release formulation designed to gradually and reliably raise serum total 25-hydroxyvitamin D (prohormone) concentrations to targeted levels (at least 30 ng/mL) while avoiding upregulation of CYP24, a cytochrome P-450 enzyme that reduces the PTH lowering potency of current vitamin D supplements. Activation of the product by the kidney is tightly regulated, preventing excessive elevation of serum calcium and related side effects which encumber current vitamin D hormone therapies and promote vascular and renal calcification. Once approved, Rayaldy will address the approximately four million CKD stage 3 and 4 patients in the US and many more, elsewhere, with SHPT and vitamin D insufficiency.

CKD is a condition characterized by a progressive decline in kidney function. The kidney is normally responsible for excreting waste and excess water from the body, and for regulating various hormones. CKD is classified in five different stages — mild (stage 1) to severe (stage 5) disease — as measured by the kidney’s glomerular filtration rate.

Vitamin D insufficiency is a condition in which the body has low vitamin D stores, characterized by inadequate blood levels of vitamin D prohormones, collectively known as 25-hydroxyvitamin D.

SHPT is a condition commonly associated with CKD in which the parathyroid glands secrete excessive amounts of PTH. SHPT arises as a result of vitamin D insufficiency or impaired kidney function that prevents sufficient production of vitamin D hormones to properly regulate calcium and phosphorus metabolism, and PTH secretion. Prolonged elevation of blood PTH causes excessive calcium and phosphorus to be released from bone, leading to elevated serum calcium and phosphorus, softening of the bones (osteomalacia) and calcification of vascular and renal tissues.

OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

About Absolute Day Trader Picks

This is a site sponsored and driven by content supplied and aggregated  by Frank Magliochetti and Parcae Capital Corporation.  It will highlight emerging growth companies and picks made by Frank Magliochetti and his team of professionals.

If you have a company interested in having our team review for our Day Trading Pick please contact us by clicking here.

Day Trader Picks

OPKO Health, Inc – World News

opko-160x160

Citicoline Products Approved for Commercialization in Spain

MIAMI--(BUSINESS WIRE)--July 24, 2013--

OPKO Health, Inc. (NYSE:OPK) announced that its Barcelona, Spain subsidiary, Pharmadiet, S.L.U., received regulatory approval from Spain’s health authority (Agencia Española de Medicamentos y Productos Sanitarios) for commercialization of its oral and injectable formulations of citicoline. Final marketing authorization is expected within 60 to 90 days.

Sales of the other citicoline product presently available in Spain, Somazina(R), exceeded $80 million in 2012. Citicoline also enjoys strong sales throughout Latin America, including those countries where OPKO maintains a growing presence.

“OPKO plans to commercialize its oral and injectable citicoline products in Europe, Latin America, and other markets as well,” said Phillip Frost, M.D., OPKO’s Chairman and Chief Executive Officer.

About Citicoline

Citicoline products are indicated for the treatment of memory disorders and behavior related to stroke, head injury, chronic disease, as well as degenerative brain disorders. Citicoline enhances the level of phosphatidylcholine in the brain.

About OPKO Health, Inc.

We are a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding expected financial performance, the market for and expected sales of citicoline products, our ability to commercialize citicoline products in Spain, Europe, Latin America and other markets, and expectations regarding timing for final marketing authorization for our citicoline products, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

 
    CONTACT: OPKO Health, Inc.

Steven D. Rubin or Juan F. Rodriguez, 305-575-4100

 
    SOURCE: OPKO Health, Inc.

 

Pharmsynthez

Company Overview

pharmsynthez

 

Pharmsynthez is an Absolute Day Trader pick hit to add to your watch list.  Take a look at the information below culled from their website

Pharmsynthez is an innovative pharmaceutical company developing new medications, technologies of drugs for organ-specific delivery and innovative methods of manufacture for pharmaceutical ingredients.

The company profile is production and sales of both officinal medicines (original OM) and active pharmaceutical ingredients (API). The company has at its disposal a research and production facility, Pharmsyntez, put into operation in 2001.

Pharmsynthez is an international company and our business extends far beyond Russia. Starting from 2000, company-manufactured medicines were made available to the Public Health Services of Ukraine and Georgia, and since 2004 they have been marketed throughout CIS countries. In chemical compounds and API production we are intensely cooperating with North-American, Canadian and European companies.

absolute day trader picks FM_edited-1

 

For More Info – Click Here for the Absolute Day Trader post.

Pharmsynthez

pharmsynthez-logo2

Frank Magliochetti – Absolute Day Trader Picks-

Pharmsynthez is a one to add to your watch list.  Take a look at the information below culled from their company  website

pharmsynthez

Pharmsynthez is an innovative pharmaceutical company developing new medications, technologies of drugs for organ-specific delivery and innovative methods of manufacture for pharmaceutical ingredients.

The company profile is production and sales of both officinal medicines (original OM) and active pharmaceutical ingredients (API). The company has at its disposal a research and production facility, Pharmsyntez, put into operation in 2001.

Pharmsynthez is an international company and our business extends far beyond Russia. Starting from 2000, company-manufactured medicines were made available to the Public Health Services of Ukraine and Georgia, and since 2004 they have been marketed throughout CIS countries. In chemical compounds and API production we are intensely cooperating with North-American, Canadian and European companies.

While developing new medications, creating new technologies of organ-specific delivery of medicines and refining medicines manufacturing methods, we are working in close relations with leading research centres in Russia, Great Britain, France and Germany using the advantages of broad international cooperation to offer our patients safer and more effective medications.

We haven’t been looking for royal roads. Our main resources are assigned to oncology, tuberculosis and other bacterial and viral infections – grave and mortal diseases taking their toll of millions of humans worldwide every year.

In the area of API manufacturing, the company focuses on production of innovative hi-tech expensive substances, until now, for the most part, imported.

Industrially developed countries impose strict quality, effectiveness and safety standards on pharmaceutical industries.

Quality management and assurance in a modern enterprise are essential and quite expensive challenges. We do set ourselves these objectives and are successfully accomplishing them.

An innovative chemical production facility intended for the manufacture of active pharmaceutical ingredients and other chemical substances was built by the Company 10 kilometres north of St. Petersburg. This project provides a good example of the symbiosis of Russian expertise in setting up science intensive chemical production facilities and producing chemicals of traditional German quality.

The facility engineering design was developed in conjunction with the St. Petersburg State Institute of Technology; Linde, German technological company, and Prikladnaya Khimiya (Applied Chemistry) Russian Research Centre, Federal State Unitarian Enterprise. The facility is equipped with new European technological and testing machinery. Upon completion, the construction project was certified by German specialists.

Mission:

The National Standard for pharmaceuticals manufacture and quality control, RF GOST R 52249-2004 (being an authentic translation of EU Pharmaceuticals Good Manufacturing Practices regulations), came into effect on January 1st, 2005. One of the purposes of the pharmaceutical industry switching to international standards is providing the country populace with modern highly effective medications of a quality adequate to that of foreign analogs but at lower retail prices.

Pharmsynthez is an active participant of a nation-wide pharmaceutical business transition to international regulations. In particular, Quality Policy and Objectives for the years 2006-2007 make provisions for preparation to ISO certification and getting enterprise quality management system ISO-certified and attested for conformity with EU GMP. When achieved, these steps will enable the Company to manufacture pharmaceuticals of international quality standard locally and establish cooperation with leading domestic and foreign manufacturers on new dosage forms (ampoules, tablets, capsules, etc.) production.

Manufacturing:

Pharmsynthez Company is an innovative production company operating its own working capital and it has been very successful in the market in recent years.

pharmsythez

The Company, unlike the majority of pharmaceutical production companies in Russia, adheres to international business standards, and having a modern high-tech pharmaceutical substances production facility, we place production orders for official medicines on the nation-best facilities and always fulfill our contractual obligations for production services.

Absolute Day Trader Picks is a growing site that encourages your participation and input – If you want the site to consider featuring your business please contact us by clicking here.

For more about Frank Magliochetti please Click Here

OPKO Health, Inc

opko-160x160

Company Overview

OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies.

opko-160x160They intend to leverage their global commercialization expertise to pursue acquisitions of commercial businesses that will both drive their growth and provide geographically diverse sales and distribution opportunities. OPKO has and may continue to make investments in other early stage companies that they perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder.

OPKO’s Focus

Recent Highlights

Since 2009, OPKO has completed national and international acquisitions of the following companies:

OURLabs, acquired by OPKO in December 2012, includes urologic, gastrointestinologic, dermapathologic, and women’s health laboratories based in Nashville, Tennessee. OURLabs operates 18 phlebotomy sites throughout the United States and is strategically positioned as OPKO’s commercial platform for the anticipated U.S. launch of 4Kscore™, a prostate cancer biomarker panel.

OPKO Diagnostics creates innovative point-of-care diagnostics technology that transition in-vitro medical diagnostics tests from the laboratory to the physician’s office and allow the performance of complex laboratory quality assays in minutes with no training and at minimal cost.

OPKO Chile markets, sells, and distributes pharmaceutical and nutraceutical products to private, hospital, and institutional markets in Chile.

OPKO EU develops, manufactures, markets, and sells a line of pharmaceutical, nutraceutical, and veterinary products throughout Europe.

OPKO FineTech develops specialty active pharmaceutical ingredients (APIs) in Israel.

OPKO Mexico manufactures, markets, sells, and distributes ophthalmic and other pharmaceutical products to private and public customers in Mexico.

OPKO continues to explore acquisition opportunities for complementary pharmaceuticals, compounds, technologies, and businesses. They expect their future growth to arise from leveraging our proprietary technology, development strengths, and pursuit of complementary and strategic acquisitions and investments.

Experienced Management Team:

OPKO has a highly experienced management team that  has demonstrated an ability to successfully build and manage pharmaceutical businesses. OPKO’s Chairman and Chief Executive Officer, Dr. Phillip Frost, founded and served as Chairman and Chief Executive Officer of IVAX Corporation, a multi-national pharmaceutical company, from 1987 until the acquisition of IVAX by Teva Pharmaceutical Industries, Limited in January 2006. Dr. Frost currently serves as Chairman of the Board of Teva. Prior to Ivax, Dr. Frost founded and served as Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough Corporation in 1986. Other senior executive officers are also veterans in the pharmaceutical industry and have extensive development, regulatory, and commercialization expertise.

OPKO’s experienced management team has the development, regulatory, and commercialization expertise and relationships able to access and facilitate excellent commercial opportunities.

OPKO recent stock activity – CLICK HERE

For Investor Relations – CLICK HERE

Press Releases of Interest – CLICK HERE

Murphy's Pub Salem, MA